☆ 4.6 Editorial Material

The role of soluble CD40L in immunosuppression

ONCOIMMUNOLOGY (2013)

期刊

ONCOIMMUNOLOGY

卷 2, 期 1, 页码 -

出版社

TAYLOR & FRANCIS INC

DOI: 10.4161/onci.22546

关键词

immunosuppression; myeloid derived suppressor cells (MDSC); regulatory T cells (Tregs); sCD40L; vaccine therapy

类别

Oncology Immunology

向作者/读者索取更多资源

Protocol

Reagent

摘要

We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumor-targeting vaccines or other therapeutic modalities.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Immunology

Role of myeloid derived suppressor cells in sepsis

M. Malavika, S. Sanju, M. R. Poorna, Veeraraghavan Vishnu Priya, Neeraj Sidharthan, Praveen Varma, Ullas Mony

Summary: This review focuses on the role of myeloid derived suppressor cells (MDSCs) in infection, sepsis, and septic shock, and their contribution to lymphopenia and immune suppression.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Review Immunology

Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells

Yudan Cui, Jingshan Cai, Wenxin Wang, Shengjun Wang

Summary: HDACIs are antitumor drugs that enhance gene transcription via epigenetic regulation, with cytotoxic properties against tumor cells. The effects of HDACIs on immunocytes in the tumor microenvironment, specifically MDSCs, are still not fully understood.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization

Christopher Groth, Rebekka Weber, Samantha Lasser, Feyza Gul Ozbay, Annina Kurzay, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky

Summary: This review summarizes the origin of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) and their relation to classical neutrophils, outlining their metastasis promoting features and promising strategies for targeting them to enhance the efficacy of cancer immunotherapy.

INTERNATIONAL JOURNAL OF CANCER (2021)

添加到收藏夹

Article Immunology

Myeloid-Derived Suppressor Cells in Patients With Acute Pancreatitis With Increased Inhibitory Function

Lili Ding, Minjie Wan, Dong Wang, Huiru Cao, Haijiao Wang, Pujun Gao

Summary: Acute pancreatitis (AP) is pancreatic or systemic inflammation, and severe acute pancreatitis (SAP) is the main cause of death for AP patients. This study found that MDSCs (myeloid-derived suppressor cells) were increased in AP patients, especially in SAP patients, and their frequency was positively correlated with disease severity. The MDSCs from SAP patients exhibited enhanced suppressive ability, which might be attributed to the overexpression of Arg-1 and ROS.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Surgery

Adjuvant conditioning induces an immunosuppressive milieu that delays alloislet rejection through the expansion of myeloid-derived suppressor cells

Jifu Ge, Weikang Pan, Noel J. Feeney, Leah Ott, Emily Anderson, Alessandro Alessandrini, Ivan Zanoni, James F. Markmann, Alex G. Cuenca

Summary: Advances in immunosuppression have been limited, and long-term morbidity associated with immunosuppression regimens remains a problem for transplant recipients. A novel administration strategy using the adjuvant alum was discovered, which expanded MDSCs and suppressed T cell proliferation. These MDSCs also facilitated the differentiation of thorn T cells into regulatory T cells. Adjuvant treatment significantly delayed alloislet rejection, and the increased IL-10 production by AC MDSCs played a critical role in their suppressor function and protective effect. Therapeutics aimed at expanding MDSCs could be a useful strategy to prevent transplant rejection and reduce the use of toxic immunosuppressive regimens.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

添加到收藏夹

Article Nutrition & Dietetics

Resveratrol Attenuates 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Induction of Myeloid-Derived Suppressor Cells (MDSC) and Their Functions

Wurood Hantoosh Neamah, Alex Rutkovsky, Osama Abdullah, Kiesha Wilson, Ryan Bloomquist, Prakash Nagarkatti, Mitzi Nagarkatti

Summary: This study demonstrates that Resveratrol (RSV), an AhR antagonist, reduces the induction and function of murine myeloid-derived suppressor cells (MDSCs) induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). RSV reverses the effects of TCDD on macrophages and dendritic cells, as well as the upregulation of critical molecules involved in TCDD-mediated induction and immunosuppressive functions of MDSCs. RSV treatment decreases the energetic demands induced by TCDD. These findings suggest the potential use of RSV to attenuate the immunosuppressive properties of MDSCs.

NUTRIENTS (2023)

添加到收藏夹

Review Immunology

Granulocytic Myeloid-Derived Suppressor Cells in Cystic Fibrosis

Samantha L. Tucker, Demba Sarr, Balazs Rada

Summary: Cystic Fibrosis is a genetic disease that causes chronic lung inflammation and infections, leading to high mortality rates. Immune system disruption in CF results in impaired immune responses, chronic infections with pathogens, and alterations in T cell and neutrophil functions. The role of P. aeruginosa and gMDSCs in T cell suppression and immune evasion in CF remains a subject of ongoing research.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection

Carlos Lamsfus Calle, Rolf Fendel, Anurag Singh, Thomas L. Richie, Stephen L. Hoffman, Peter G. Kremsner, Benjamin Mordmuller

Summary: Malaria can lead to severe complications and chronic infections, causing conditions like anemia and immunologic hyporesponsiveness. The study on controlled human malaria infection revealed that malaria-induced immunosuppression, with circulating PMN-MDSC serving as an early indicator of infection.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Immunology

The role of myeloid derived suppressor cells in musculoskeletal disorders

Yi Ren, Henrik Baecker, Michael Mueller, Arne Kienzle

Summary: The immune system has a significant impact on bone metabolism in various pathological and inflammatory conditions. Myeloid-derived suppressor cells (MDSCs) are a group of cells that can suppress immune responses and mediate bone remodeling. They can both cause bone erosion through differentiation into osteoclasts and alleviate immune reactions. This review discusses the influence of MDSCs on bone metabolism and potential therapeutic targets for improving bone health.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2)

David C. Soler, Amber Kerstetter-Fogle, Andrew B. Young, Pat Rayman, James H. Finke, Sarah M. Debanne, Kevin D. Cooper, Jill Barnholtz-Sloan, Andrew E. Sloan, Thomas S. McCormick

Summary: This study focused on human monocytic Myeloid-Derived Suppressor cells (Mo-MDSC) and identified Vanin-2 protein as a novel biomarker highly enriched in healthy individuals, but with an inverse correlation to grade in glioma patients. CD14(+)VNN2(high) monocytes may mark a monocytic population similar to Mo-MDSC only in healthy subjects, which could be useful for tumor diagnoses.

MOLECULAR IMMUNOLOGY (2022)

添加到收藏夹

Article Cell Biology

Extracellular vesicles released by myeloid-derived suppressor cells from pregnant women modulate adaptive immune responses

Stefanie Dietz, Julian Schwarz, Jessica Ruehle, Martin Schaller, Birgit Fehrenbacher, Alexander Marme, Evi Schmid, Andreas Peter, Christian F. Poets, Christian Gille, Natascha Koestlin-Gille

Summary: Research demonstrates that GR-MDSC exosomes during pregnancy have significant immune-modulatory effects in vitro, such as suppressing T-cell proliferation, inducing regulatory T-cells, indicating their potential as an interesting therapeutic target for immunological pregnancy complications.

CELLULAR IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis

Vipul K. Singh, Arshad Khan, Yitian Xu, Sunny Mai, Licheng Zhang, Abhishek Mishra, Blanca I. Restrepo, Ping-Ying Pan, Shu-Hsia Chen, Chinnaswamy Jagannath

Summary: This study demonstrates that antagonism of LILRB2 can reprogram human MDSCs into M1 macrophages, leading to enhanced killing of Mycobacterium tuberculosis. This finding provides a potential avenue for targeting MDSCs to eradicate Mtb.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Immunology

Myeloid-Derived Suppressor Cells: The Expanding World of Helminth Modulation of the Immune System

Mary M. Stevenson, Rajesh M. Valanparambil, Mifong Tam

Summary: The article suggests that immune suppression caused by helminth infections may be related to myeloid-derived suppressor cells (MDSC), and the data collected so far support this hypothesis. Future strategies targeting MDSC could enhance immune responses to eliminate adult worms and prevent reinfection.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report

Malika Davids, Anil Pooran, Liezel Smith, Michele Tomasicchio, Keertan Dheda

Summary: This study found that circulating myeloid-derived suppressor cells (MDSCs) are induced during active TB disease, with higher frequencies in active TB patients compared to those with latent TB infection. These MDSCs can suppress T-cell proliferation and subvert mycobacterial containment, suggesting potential implications for vaccine and immunotherapeutic interventions against TB. Further studies are needed to understand the mechanisms underlying the effects of MDSCs.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Myeloid cells in sepsis-acquired immunodeficiency

Fabienne Venet, Julie Demaret, Morgane Gossez, Guillaume Monneret

Summary: Sepsis profoundly impacts immune homeostasis by disrupting myeloid cell response. This disruption includes mechanisms such as apoptosis, endotoxin tolerance, and metabolic failure, leading to increased risk of adverse outcomes in patients. Therapeutic strategies targeting these defects primarily involve the use of immunoadjuvant molecules.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

A Comparison of F-18-DCFPyL, F-18-NaF, and F-18-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer

Aloyse Fourquet, Adrian Rosenberg, Esther Mena, Joanna J. Shih, Baris Turkbey, Maxime Blain, Ethan Bergvall, Frank Lin, Stephen Adler, Ilhan Lim, Ravi A. Madan, Fatima Karzai, James L. Gulley, William L. Dahut, Bradford J. Wood, Richard Chang, Elliot Levy, Peter L. Choyke, Liza Lindenberg

Summary: This study compared the use of different PET tracers (F-18-DCFPyL, F-18-NaF, and F-18-FDG) in men with metastatic prostate cancer. The results showed that F-18-DCFPyL was the most effective in detecting metastatic lesions, while F-18-NaF was better at detecting bone metastases. The study also found that there were differences in the detection rates of the same lesion using different tracers.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Oncology

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H. Taylor, Jaafar Bennouna, Deborah J. Wong, Karen Kelly, Claire Verschraegen, Marcis Bajars, Juliane Manitz, Mary Ruisi, James L. Gulley

Summary: This study found that approximately 11% of patients with advanced non-small-cell lung cancer received 2 years or more of avelumab treatment in a large trial, and experienced prolonged response or continued clinical benefit.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.

Luke Meininger, Ravi Amrit Madan, Nicole Toney, Renee Nicole Donahue, Margaret Elena Gatti-Mays, Julius Strauss, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Lisa M. Cordes, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Keith T. Schmidt, Fatima Karzai, Marijo Bilusic, Lisa M. Cordes, Cindy H. Chau, Cody J. Peer, Susan Wroblewski, Alwin D. R. Huitema, Jan H. M. Schellens, James L. Gulley, William L. Dahut, William D. Figg, Ravi A. Madan

Summary: This article reports the results of a trial evaluating the efficacy of NLG207 in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide. The study found that the combination treatment was not well tolerated in patients, leading to the termination of the study.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors

Cristina Mullenix, Madison Ballman, Haobin Chen, Shannon Swift, Meredith J. McAdams, Yo-Ting Tsai, Renee N. Donahue, Trina Poretta, Sarthak Gupta, Patrick J. Loehrer, Jeffrey Schlom, James L. Gulley, Arun Rajan

Summary: ICIs have revolutionized cancer treatment, but immune-mediated toxicity is a concern for TETs patients. The cases presented in this report highlight the spectrum of immune-mediated musculoskeletal adverse events in TETs patients.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

Juliane Manitz, Sandra P. D'Angelo, Andrea B. Apolo, S. Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L. Gulley

Summary: This study compared tumor responses evaluated by RECIST 1.1 and immune-related RECIST (irRECIST) in patients with different types of tumors treated with avelumab. The correlation between progression-free survival (PFS) and overall survival (OS) was also evaluated. The results showed that irRECIST could identify a subset of patients classified as progressive disease (PD) by RECIST 1.1 but with immune-related disease control by irRECIST, providing clinically relevant information. However, as a surrogate endpoint for OS in the whole population, immune-related PFS did not show improved predictive value compared with PFS by RECIST 1.1.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer

Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley

Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Review Oncology

Molecular Pathways and Mechanisms of TGFb in Cancer Therapy

Mary Helen Barcellos-Hoff, James L. Gulley

Summary: Despite the increasing number of TGFI3 inhibitors tested in cancer patients, there has been no clinical benefit achieved yet. The main obstacle to effective TGFI3 inhibition is the diverse mechanisms by which TGFI3 promotes tumor growth. TGFI3 is involved in regulating DNA repair and immune suppression, which can be used to synergize genotoxic therapy and immunotherapy for the benefit of cancer patients.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation

Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg, Mark J. Ratain

Summary: Atezolizumab, a humanized monoclonal antibody against PD-L1, was approved in 2016. Standard dose regimens result in high plasma concentrations, indicating the need for alternative dosing strategies to reduce exposure burden.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz

Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley

Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen

Summary: PSMA expression is maintained in all stages of prostate cancer. In a phase 1 study, a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells showed manageable cytokine release syndrome and temporary decline in PSA in patients with metastatic castration-resistant prostate cancer. Treatment-related deaths and radiographic responses were not observed. PSMA is a potential therapeutic target for T-cell redirection in prostate cancer.

CLINICAL GENITOURINARY CANCER (2023)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Michael B. Atkins, Paolo A. Ascierto, David Feltquate, James L. Gulley, Douglas B. Johnson, Nikhil Khushalani, Jeffrey Sosman, Timonthy A. Yap, Harriet Kluger, Ryan J. Sullivan, Hussein Tawbi

Summary: Immunotherapy alone does not work for all tumors, so combining it with signal transduction inhibitors, such as antiangiogenic therapies, can enhance its effectiveness. Combination therapies with immunotherapy have shown improved antitumor activity in various solid tumor settings and have received regulatory approval for the treatment of several types of cancer. However, many patients still experience progression after combination treatment, highlighting the need for new strategies to address resistance to immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Oncology

Vaccinating against cancer: getting to prime time

Ryan Chang, James L. Gulley, Lawrence Fong

Summary: Immunotherapies, such as immune checkpoint inhibitors and cellular therapies, have revolutionized cancer treatment, but the development of successful cancer vaccines remains challenging. Only two vaccines have shown improved survival in advanced disease: sipuleucel-T and talimogene laherparepvec, which target specific antigens and utilize tumors in situ to prime responses. In this review, we examine the challenges and opportunities in developing therapeutic cancer vaccines.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Biochemical Research Methods

MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays

Joshua A. Welsh, Bryce Killingsworth, Julia Kepley, Tim Traynor, Sean Cook, Jason Savage, Jenn Marte, Min-Jung Lee, Hoyoung M. Maeng, Michelle L. Pleet, Setty Magana, Andre Gorgens, Cecile L. Maire, Katrin Lamszus, Franz L. Ricklefs, Maria J. Merino, W. Marston Linehan, Tim Greten, Tomer Cooks, Curtis C. Harris, Andrea Apolo, Asim Abdel-Mageed, Alexander R. Ivanov, Jane B. Trepel, Matthew Roth, Mercedes Tkach, Aleksandar Milosavljevic, Clotilde Thery, Amy LeBlanc, Jay A. Berzofsky, Eytan Ruppin, Kenneth Aldape, Kevin Camphausen, James L. Gulley, Ionita Ghiran, Steve Jacobson, Jennifer C. Jones

Summary: Extracellular vesicles (EVs) carry various types of proteins and nucleic acids, and can provide a retrospective snapshot of cell state through liquid biopsies. Multiplex assays for high-parameter EV protein detection are still being developed. To facilitate EV repertoire studies, we developed MPAPASS software for stitched multiplex analysis, EV database-compatible reporting, and visualization of EV repertoires.

CELL REPORTS METHODS (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.